binding affinity News and Research

RSS

SARS-CoV-2 mutations allow escape from clinical monoclonal antibodies

A new research paper recently uploaded to the preprint server bioRxiv by Jesse D. Bloom et al. (22nd Feb 2021) aims to map all of the currently circulating SARS-CoV-2 lineages with resistance towards LY-CoV555 and LY-CoV016, and document the specific mutations that confer resistance, ultimately suggesting that future monoclonal antibody cocktails should target a more diverse range of epitopes.

23 Feb 2021

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

A new study sheds light on the threat posed by future zoonotic coronaviruses to make similar leaps across species barriers to infect human beings and cause other pandemics.

22 Feb 2021

Gold nanoparticles investigated as part of in vitro tool for SARS-CoV-2 drug screening

Scientists have measured the interaction of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein with nano-gold colloids. These nanoparticles functionalized with the S protein have different spectroscopic signals allowing for new information about the protein to be extracted.

21 Feb 2021

A promising strategy to improve functional capacity of damaged muscle

Muscle is the largest organ that accounts for 40% of body mass and plays an essential role in maintaining our lives.

21 Feb 2021

Llama-derived nanobodies show neutralizing activity against SARS-CoV-2 variants of concern in vitro

A new study reports the development of nanoantibodies (nAbs) – also called or nanobodiesTM or single-domain antibodies – that effectively bind the SARS-CoV-2 spike protein from the ancestral Wuhan variant as well as the recently detected UK and South African variants.

19 Feb 2021

Chicken-derived antibody shows potent neutralizing capacity against SARS-CoV-2 in vitro

Researchers report on a Chicken-derived antibody against SARS-CoV-2, offering preliminary data on a potential therapeutic for COVID-19 warranting further research.

19 Feb 2021

How does the SARS-CoV-2 E484K mutation increase viral fitness?

How do mutations benefit SARS-CoV-2? To explore this, a team of researchers from China took a closer look at the physical interactions that occur between the proteins after viral mutation.

19 Feb 2021

New N501Y SARS-CoV-2 mutations increase binding to host cell receptor

A team of researchers used several assays, atomic force microscopy, and simulations to determine that the N501Y mutation in the virus’s receptor-binding domain (RBD) increased the interaction of the virus with the angiotensin-converting enzyme 2 (ACE2) receptor.

17 Feb 2021

Bats and pangolins in Southeast Asia harbor SARS-CoV-2-related coronaviruses, study finds

A new study has reported evidence that SARS-CoV-2-related coronaviruses (SC2r-CoVs) are circulating in bats in Southeast Asia. This has extended the geographical area where SC2r-CoVs are found, underscoring the urgency of identifying the immediate ancestor of SARS-CoV-2.

17 Feb 2021

British and South African SARS-CoV-2 variants show some resistance to neutralizing antibodies

Researchers in France report impaired neutralization of two new SARS-CoV-2 variants by antibodies induced by vaccination or natural infection.

16 Feb 2021

Clonally expanded plasma cell lineages in SARS-CoV-2 produce specific neutralizing antibodies

A new preprint research paper posted to the bioRxiv server provides a greater understanding of the aspect of humoral immunity against the virus – the plasma cells that pour out a flood of specific antibodies targeting various epitopes on the pathogen.

16 Feb 2021

Mink-derived SARS-CoV-2 mutations reduce antibody effectiveness

A new preprint research paper posted to the bioRxiv* server shows that these mutations disrupt inhibition by neutralizing antibodies, both natural and therapeutic.

16 Feb 2021

Immunosuppressive therapies may be linked to severe COVID-19 in those with multiple sclerosis

A new study examines the associations between immunosuppressive disease-modifying therapies (DMTs) used in MS with adverse outcomes in an international cohort of patients with MS COVID-19.

15 Feb 2021

Naïve B cells can neutralize SARS-CoV-2 via RBD recognition

A new preprint research paper posted to the bioRxiv server demonstrates the potential of using the pre-existing protective responses to produce a broad-spectrum neutralizing response against not just SARS-CoV-2 but other future pathogens.

14 Feb 2021

Emergence and transmission of UK SARS-CoV-2 variant in the US

Researchers describe the impending rise to dominance of the B.1.1.7 (UK) variant in the US. Understanding this development will help to shape preventive action to reduce the infection and mortality rates.

9 Feb 2021

Could graphene be an effective antiviral platform against SARS-CoV-2?

The urgent need for novel therapeutics has spurred investigation into broad-spectrum inhibitors of viral infection and replication. A new study describes the antiviral activity of synthesized graphene platforms, pointing to new therapeutic approaches against this virus.

8 Feb 2021

COVID-19 pandemic and nanotechnology

Writing in the International Journal of Nanomedicine, Professor Dongki Yang, from the Department of Physiology, Gachon University, South Korea, has reviewed the available knowledge on the coronaviruses, current approaches to tackle the newly emerged SARS-CoV-2 infection, and the innovative application of nanotechnology in the COVID-19 pandemic.

8 Feb 2021

Alpaca nanobodies neutralize SARS-CoV-2 in vitro

A new preprint research paper posted to the bioRxiv server reports the development of highly effective neutralizing nanobodies targeting the viral receptor-binding domain (RBD), thus disrupting its engagement with the host cell angiotensin-converting enzyme 2 (ACE2) receptor.

4 Feb 2021

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Among these is the B.1.1.7 SARS-CoV-2 variant, with its characteristic N501Y mutation. A new preprint on the bioRxiv server reports the impact of this mutation on CD4 T cell responses, including antigen presentation on cells expressing Major Histocompatibility Complex (MHC) class II molecules.

4 Feb 2021

South African SARS-CoV-2 variant neutralized by two Chinese vaccines in case study

A new study offers some reassuring findings, reporting the successful neutralization of the South African SARS-CoV-2 variant of concern (VOC) 501Y.V2 by two vaccines developed in China.

4 Feb 2021

binding affinity News and Research

SARS-CoV-2 mutations allow escape from clinical monoclonal antibodies

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

Gold nanoparticles investigated as part of in vitro tool for SARS-CoV-2 drug screening

A promising strategy to improve functional capacity of damaged muscle

Llama-derived nanobodies show neutralizing activity against SARS-CoV-2 variants of concern in vitro

Chicken-derived antibody shows potent neutralizing capacity against SARS-CoV-2 in vitro

How does the SARS-CoV-2 E484K mutation increase viral fitness?

New N501Y SARS-CoV-2 mutations increase binding to host cell receptor

Bats and pangolins in Southeast Asia harbor SARS-CoV-2-related coronaviruses, study finds

British and South African SARS-CoV-2 variants show some resistance to neutralizing antibodies

Clonally expanded plasma cell lineages in SARS-CoV-2 produce specific neutralizing antibodies

Mink-derived SARS-CoV-2 mutations reduce antibody effectiveness

Immunosuppressive therapies may be linked to severe COVID-19 in those with multiple sclerosis

Naïve B cells can neutralize SARS-CoV-2 via RBD recognition

Emergence and transmission of UK SARS-CoV-2 variant in the US

Could graphene be an effective antiviral platform against SARS-CoV-2?

COVID-19 pandemic and nanotechnology

Alpaca nanobodies neutralize SARS-CoV-2 in vitro

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

South African SARS-CoV-2 variant neutralized by two Chinese vaccines in case study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News